|Paper title||Preliminary Experience with a Novel Drug Coating Balloon Catheter for Symptomatic Intracranial High-grade Stenosis|
|Form of presentation||Poster|
Objective: Intracranial arteriosclerotic disease is a relevant cause of ischemic stroke worldwide. Despite best medical treatment, the re-occurrence rate is high. Because of the discouraging SAMMPRIS trial , neurovascular treatment remained as a second line therapy. Since, there has been tremendous advance in device technology. SeQuent Please NEO (B.Braun, Melsungen, Germany) is a novel polymer-free, drug coated (paclitaxel/iopromide) balloon (DCB) primarily designed for cardiology. Because of its high flexibility and pushability it seems to be suitable also for intracranial use. Furthermore, it offers a sustained anti-proliferative effect and natural vessel restoration. The aim of this case series was to assess feasibility and safety of Sequent Please NEO in symptomatic intracranial high-grade stenosis.
Method: A single-center case series of 12 patients with symptomatic intracranial high-grade stenosis between 09/2016–01/2018 treated with SeQeunt Please NEO DCB executed at a tertiary stroke center in Switzerland.
Results: 12 patients (100% men, median ages 73 years (interquartile range (IQR) 70-77) were treated with SeQuent Please NEO. Median pre-treatment carotid stenosis grade was 78% (IQR 75-80) with 2 mid-basilar, 5 internal cerebral artery and 5 vertebral artery lesions. Median post-treatment stenosis grade was 50% (IQR 45-52). Successful angioplasty was achieved in all cases without technical failure and no peri-procedural re-occlusion rates and no mortality rate at follow-up.
Conclusion: SeQuent Please NEO CDB demonstrates to be feasible and safe in symptomatic intracranial high-grade stenosis. Therefore, it might constitute a promissing alternative to medical treatment.